Search Results for keywords:"Insys Therapeutics"

The Food and Drug Administration (FDA) issued a permanent debarment order against Alec Burlakoff under the Federal Food, Drug, and Cosmetic Act. Burlakoff was convicted of a felony involving illegal activities with a drug called SUBSYS while working at Insys Therapeutics. His actions included bribing doctors to prescribe the drug, often to patients who did not have cancer. As a result, Burlakoff is banned from providing services related to drug product applications, and there are penalties for any approved drug product applications that employ him during this period.

The Food and Drug Administration (FDA) is issuing a permanent debarment order against Joseph A. Rowan, preventing him from working with any businesses that have drug product applications. This order results from Mr. Rowan's felony conviction related to illegal activities with the drug SUBSYS while at Insys Therapeutics. He was found guilty of racketeering, mail fraud, and wire fraud, including bribing doctors to prescribe SUBSYS to patients without cancer and misleading insurers. Mr. Rowan was notified of this debarment decision and waived his right to contest it by not requesting a hearing.

The Food and Drug Administration (FDA) has issued an order under the Federal Food, Drug, and Cosmetic Act to permanently ban Sunrise Lee from working with any person or company that has a drug product application. This decision follows her felony conviction for racketeering related to the regulation of a drug product. Lee, who previously worked in a leadership role at Insys Therapeutics, was found guilty of participating in a conspiracy to bribe medical practitioners to prescribe a fentanyl-based drug called SUBSYS. Despite being notified of the proposed ban and given a chance to contest it, Lee did not respond, resulting in a waiver of her right to a hearing.